ISRN Medicinal Chemistry

Volume 2013 (2013), Article ID 107840, 8 pages

http://dx.doi.org/10.1155/2013/107840

Research Article

Sulfonamide Based β-Carbonic Anhydrase Inhibitors: 2D QSAR Study

Meenakshi N. Deodhar, Priyanka L. Khopade, and Mahesh G. Varat

Department of Chemistry, PDEA’s S. G. R. S. College of Pharmacy, University of Pune, Pune 412203, India

Received 14 August 2013; Accepted 10 October 2013

Academic Editors: A. Afantitis, R. Giridhar, and S. Rivara

Copyright © 2013 Meenakshi N. Deodhar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

The carbonic anhydrases (CAs) (or carbonate dehydratases) form a family of metalloenzymes that catalyze the rapid interconversion of carbon dioxide and water to bicarbonate and protons (or vice versa), a reversible reaction that occurs rather slowly in the absence of a catalyst. The β-CAs have been characterized in a high number of human pathogens, such as the fungi/yeasts Candida albicans, Candida glabrata, Cryptococcus neoformans, and Saccharomyces cerevisiae and the bacteria Helicobacter pylori, Mycobacterium tuberculosis, Haemophilus influenzae, Brucella suis, and Streptococcus pneumonia. The β-CAs in microorganisms provide physiological concentration of carbon dioxide and bicarbonate (CO₂/) for their growth. Inhibition of β-CAs from the pathogenic microorganism is recently being explored as a novel pharmacological target to treat infections caused by the these organisms. The present study aimed to establish a relationship between the β-CAs inhibitory activity for structurally related sulphonamide derivatives and the physicochemical descriptors in quantitative terms. The statistically validated two-dimensional quantitative structure activity relationship (2D QSAR) model was obtained through multiple linear regression (MLR) analysis method using Vlife molecular design suits (MDS). Five descriptors showing positive and negative correlation with the β-CAs inhibitory activity have been included in the model. This validated 2D QSAR model may be used to design sulfonamide derivatives with better inhibitory properties.

1. Introduction

The CAs belong to the family of metalloenzymes that catalyze the rapid interconversion of carbon dioxide and water to bicarbonate and protons (or vice versa), a reversible reaction that occurs rather slowly in the absence of a catalyst. The active site of most carbonic anhydrases contains a zinc ion [1]. Genetically five different types of CAs enzymes are known till date. The α-CAs are present in vertebrates, protozoa, algae, and some bacteria and also in cytoplasm of green plants [2]. While the β-CAs are predominantly found in bacteria, algae, chloroplasts of both mono- and dicotyledons and some fungi and archaea [3], the γ-CAs are found in archaea and some bacteria [4]. Both the δ-and ζ-CAs forms are present only in marine diatoms [5].

These enzymes which catalyze the interconversion between carbon dioxide and bicarbonate, with release of a proton, are involved not only in pH homeostasis and regulation but also in biosynthetic reactions, such as gluconeogenesis and ureagenesis in animals, CO₂ fixation (in plants and algae), and electrolyte secretion in a variety of tissues/organs, with many of the 16 mammalian CAs isozymes being the established drug targets for design of diuretics, antiglaucoma, antiepileptic, antiobesity, and/or anticancer agents [6–10].

The first bacterial CA to be recognized as a β-CAs was the CynT gene of Escherichia coli [11]. More than a dozen eubacterial β-CAs are now known [12], including enzymes from common pathogens such as Helicobacter pylori, Mycobacterium tuberculosis, and Salmonella typhimurium. β-CAs are also known in the Archaea (Methanobacterium thermoautotrophicum) [13], in yeast (Saccharomyces cerevisiae) [14], cyanobacteria (Synechocystis PCC6803) [15], carboxysomes of chemoautotrophic bacteria (Halothiobacillus neapolitanus) [16], and in green (Chlamydomonas reinhardtii) [17] and red algae (Porphyridium purpureum) [18].

The β-CAs in a microorganism provide physiological concentration of carbon dioxide and bicarbonate () for its growth. Thus, inhibition of β-CAs from the pathogenic microorganism is emerging as a novel pharmacological target to treat infections caused by them [19].

QSAR is a computerised statistical method which tries to explain the observed variance in the biological effect of compounds as a function of molecular changes caused by the nature of substituent. The quantitative structure-activity relationship (QSAR) approach became very useful and largely widespread for the prediction of biological activities, particularly in drug design. This approach is based on the assumption that the variations in the properties of the compounds can be correlated with changes in their molecular features [20].

Several agents belonging to different chemical classes like sulfonamides, sulfamates, aromatic and aliphatic carboxylates, boronic acids, dithiocarbamates, and so forth have been reported to cause β-CAs inhibition in the in vitro inhibition studies [21–31]. Amongst these, sulphonamide derivatives have shown especially good β-CAs inhibitory activity and thus display a potential for development as effective antimicrobial agents [29]. While there is a report that correlates the structures of some sulphonamide derivatives with their α-CAs inhibitory activity [32], no attempts have so far been made to correlate the structure of reported β-CAIs with their inhibitory activity. Hence, it was thought appropriate to perform a QSAR study to understand the correlation between the physicochemical parameters and the β-carbonic anhydrase inhibitory (β-CAI) activity of the sulphonamide derivatives reported in the literature. It is expected that such 2D QSAR studies will provide better tools for rational design of promising β-CAIs.

2. Methodology

2.1. Material and Methods

All molecular modeling studies were performed using the VLife MDS [33]. The studies were carried out on Dell PC with a Pentium IV processor and Windows XP operating system. The structures of all compounds were sketched and cleaned in Chem Draw Ultra 8.0 version [34]. Energy minimization and geometry optimization were conducted using the merck molecular force field (MMFF) method with the root mean square gradient set to 0.01 kcal/molÅ and the iteration limit to 10, 000.

The structure of sulphonamide derivatives along with their inhibitory activity () against Candida albicans (Nce103) were taken from literature [21, 22, 29] and the data is presented in Tables 1, 2, and 3. These reported sulphonamide derivatives have been assayed for their CO₂ hydration activity using an applied photophysics instrument [35]. The β-CAI activity data have been expressed as the negative logarithm (p) on the molar basis and regarded as dependant variable for quantitative analysis. A total of 65 molecules were divided into training and a test set to ensure external validation of model derived from the appropriate descriptors. Nearly 30% of the molecules, from total population, have been selected as test molecules by manual selection method. Selection of molecules in the training set and test is a key feature of any QSAR model. Therefore, care was taken while selecting the test set that it should contain the representative structure from the whole data set.

Table 1: Structure and β-CAs inhibitory activity of benzenesulfonamides.

Comp. no.

Activity in

a01
H
NH₂
H
H
H
H
−0.035

a02
H
H
H
NH₂
H
H
−0.882

a04
H
H
H
CH₃
H
H
−0.080

a05
H
H
H
(CH₂)₂COOH
H
H
−0.106

a06
H
H
H
CH₂-NH₂
H
H
−0.044

a07
H
H
H
(CH₂)₂-NH₂
H
H
−0.504

a08
H
H
F
NH₂
H
H
−0.093

a09
H
H
Cl
NH₂
H
H
−0.128

a10
H
H
Br
NH₂
H
H
0.389

a11
H
H
I
NH2
H
H
0.143

a14
H
H
SO₂NH₂
NH₂
CF₃
H
−0.786

a15
H
H
SO₂NH₂
NH₂
Cl
H
0.058

a16
—
—
—
—
—
—
0.079

a17
—
—
—
—
—
—
−0.139

a18

H
H
H
H
H
−0.038

a19

H
H
NH₂
H
H
−0.117

a20

H
H
NH₂
H
H
0.138

a23

H
H
SO₂NH₂
H
H
−0.044

a25
—
—
—
—
—
—
−0.111

a26
H
H
H
CH₂-OH
H
H
0.416

a27
H
H
H
COOH
H
H
0.064

a41
H
H
H
(CH₂)₂-OH
H
H
−0.082

Table 2: Structure and β-CAs inhibitory activity of phenylindole-5-sulfonamides derivatives.

Comp. no.
2
3
4
5
6
Activity in

p01
H
H
H
H
H
1.070

p02
CH₃
H
H
H
H
1.107

p03
H
CH₃
H
H
H
1.366

p04
H
H
CH₃
H
H
1.283

p05
F
H
H
H
H
1.327

p06
H
F
H
H
H
1.267

p07
H
H
F
H
H
1.214

p08
Cl
H
H
H
H
1.267

p09
H
Cl
H
H
H
1.283

p10
H
H
Cl
H
H
1.259

p11
Br
H
H
H
H
1.091

p12
H
Br
H
H
H
1.060

p13
H

Br
H
H
1.026

p14
H
OCH₃
H
H
H
0.892

p15
F
F
F
F
F
2.124

Table 3: Structure and β-CAs inhibitory activity of ureido-substituted benzenesulfonamides derivatives.

Comp. no.
R
Activity in

u01
–(sulfanilamide)
−0.035

u02
Ph
0.403

u03
PhCH₂
0.262

u04
Ph₂CH
−0.598

u05
4-FC₆H₄
1.375

u06
4-ClC₆H₄
1.207

u07
4-BrC₆H₄
1.346

u08
4-IC₆H₄
1.371

u09
4-CF₃C₆H₄
1.214

u10
3,5-CF₃C₆H₄
1.232

u11
2,3,4,5,6-FC₆H₄
1.420

u12
2-OCH₃C₆H₄
0.153

u13
4-CH₃CO-C₆H₄
1.536

u14
2-isopropyl-C₆H₄
−0.537

u15
4-isopropyl-C₆H₄
0.449

u16
4-n-butyl-C₆H₄
1.301

u17
4-oxybutyl-C₆H₄
1.295

u18
4-n-octyl-C₆H₄
1.338

u19
4-NCC₆H₄
1.271

u20
2-NCC₆H₄
0.486

u21
4-PhOC₆H₄
2.468

u22
2-PhC₆H₄
0.527

u23
3-O₂NC₆H₄
1.396

u24
4-MeO-2-MeC₆H₃
1.274

u25
9H-Fluoren-2-yl
0.241

u26
Cyclopentyl
0.247

u27
3,5-Me₂C₆H₃
1.181

u28
Indan-5-yl
1.143

2.2. Descriptor Calculation

2D QSAR study requires the calculation of molecular descriptors. A large number of theoretical 2D individual descriptors such as Mol. Wt.,Volume, XlogP, and smr; physiochemical such as Estate Numbers, Estate contributions, Polar Surface Area, Element Count, Dipole moment, and Hydrophobicity XlogpA, Hydrophobicity SlogpA; and topological such as T_2_Cl_6, T_C_Cl_6, T_T_S_7, and T_T_Cl_7 type were computed. A total of 736 descriptors were calculated by QSAR Plus module within VLife MDS. Highly correlated descriptors were removed. Similarly descriptors having same values were also ignored. The reduced set of descriptors was then treated by Forward-Backward Stepwise Variable Selection for further reduction of nonsignificant descriptors and finally only five significant descriptors were considered in our 2D QSAR analysis.

2.3. Data Sets

2.3.1. Model-1

The training set contained 45 molecules: a01, a02, a04, a05, a06, a07, a09, a10, a11, a14, a15, a17, a18, a19, a23, a25, a27, p01, p02, p05, p06, p07, p08, p09, p10, p11, 12, p14, u01, u02, u03, u05, u07, u08, u09, u10, u14, u15, u16, u17, u19, u20, u22, u23, and u25.

The test set contained 20 molecules: a08, a16, a20, a26, a41, p03, p04, p13, p15, u04, u06, u11, u12, u13, u18, u21, u24, u26, u27, and u28.

2.3.2. Model-2

The training set contained 43 molecules: a01, a04, a07, a09, a11, a15, a19, a20, a23, a27, p01-p15, u01, u02, u03, u04, u05, u07, u08, u09, u10, u12, u13, u14, u15, u18, u19, u20, u23, u24, u27, and u28.

The test set contained 19 molecules: a02, a05, a06, a08, a10, a14, a16, a17, a18, a25, a26, a41, u03, u06, u07, u11, u16, u17, and u22.

2.4. Model Development

The 2D QSAR model was generated by MLR method by using V-Life MDS. The model shows the relation between the biological activity (dependant variable) and molecular descriptors (independent variables) by using linear equations. This method of regression estimates the values of the regression coefficients by applying least square curve fitting method. MLR is the traditional and standard approach for multivariate data analysis. Multivariate analysis is the analysis of multidimensional data matrices by using statistical methods. Such data metrices can involve dependent and/or independent variables. For getting reliable results, parameters were set such that the regression equation should generate number of independent variables (descriptors) 5 times less than that of compounds or molecules.

2.5. Statistical Analysis

Statistical quality of generated model was judged based on parameters such as squared correlation coefficient , crossed validated, which is relative measure of quality of fit and Fischer’s value-test which represents-ratio between the variance of calculated and residual variance, and pred_[36]. The best way to evaluate quality of regression model is internal validation of QSAR model. Mostly to check internal validation, leave-one-out (LOO) cross-validation method is used. In LOO method, one object (one biological activity value) is eliminated from training set and training dataset is divided into subsets (number of subsets = number of data points) of equal size. Model is built using these subsets and dependent variable value of the data point that was not included in the subset is determined, which is a predicted value. Mean of predicted will be same forand LOO (cross-validated correlation coefficient value) since all the data points will be sequentially considered as predicted in LOO subset. Same procedure is repeated after elimination of another object until all objects have been eliminated once. To calculate , the following equation was used:

where,, andare predicted, actual, and mean values of the , respectively.is the predictive residual error sum of squares (PRESS). Definitive validity of model is examined by mean of external validation also, which evaluates how well equation generalizes. To calculate the pred_, the following equation was used:

whereandare predicted and observed activity values, respectively, of test set compounds, andis the mean activity value of training set. Statistical significance of these models was further supported by “fitness plot” obtained for each model; this is a plot of experimental versus predicted activity of training and test set compounds and provides an idea about how fit the model was trained and how well it predicts activity of external test set (Figure 2) [37–39].

3. Results and Discussion

MLR analysis was performed using Vlife MDS 3.5 on sulphonamide derivatives taken from literature [21, 22, 29]. For selection of variables a two-way stepping algorithm was used. The following MLR QSAR model-1 (3) was generated:

The above model-1 (3) was not found to be satisfactory. Thus, to improve the quality of model, outliers (u21, u25, and u26) were identified from data set by calculating residuals value (Observed activity-Predicted activity) and removed. Compounds that have unexpected biological activity and are unable to fit in a QSAR model and are known as outliers [40]. Using data set (model-2, 2.3), new model-2 was generated:

From model-2 (4) we can conclude that using the two-way stepping algorithm, the most significant descriptors contributing to model are chi3cluster, SsssCHCount, and Polar surface area including P and S, K3alpha, and SsssOCount. The description of the descriptors used in the model is given in Table 4. Generated QSAR model shows high squared correlation coefficient between descriptors (chi3cluster, SsssCHCount, and Polar surface area including P and S, K3alpha, and SsssOCount) and β-CAI activity against Candida albicans Nce103. The squared correlation coefficient also explains 90% of the variance in biological activity. Cross-validation of model was performed by LOO method. Thequalifies it to be a valid model.

Table 4: Description of 2DQSAR model descriptors.

Descriptor
Type of physicochemical descriptor
Meaning

chi3cluster
Cluster
This descriptor signifies simple 3rd-order cluster chi index in a compound

SsssCHcount
Estate number
This descriptor defines the total number of –CH group connected with three single bond

Polar surface area including P and S
Polar surface area
Total volume of surface area including phosphorus and sulphur

k3alpha
Kappa
This descriptor signifies third alpha modified shape index

SssOcount
Estate number
This descriptor defines the total number of oxygen connected with two single bonds

The contribution graph for 2D QSAR model (Figure 1) reveals that the descriptors chi3cluster and k3alpha are contributing 44.0% and 08%, respectively. Three more descriptors SsssCHcount and Polar surface area including P and S and SssOcount are contributing inversely 30.30%, 10.0%, and 02.0%, respectively, to biological activity.

Figure 1: Contribution graph for various descriptors used in the model.

Figure 2: Data fitness plot.

Figure 2 shows the data fitness plot of model (4). The plot is an idea about linearity fit between the observed and predicted activity.

The correlation matrix given in Table 5 strongly supports the fact that no two descriptors used in model are correlated. The predicted activity for the molecules used in generating and testing the 2D QSAR model using (4) is presented in Table 6.

Table 5: Correlation matrix model Equation (4).

Descriptors
chi3cluster
K3alpha
SsssCHcount
SssOcount
Polar surface area including P and S

chi3cluster
1
0.27
0.12
0.06
0.36

K3alpha
0.27
1
0.27
0.09
−0.1

SsssCHcount
0.12
0.27
1
−0.07
−0.2

SsssOcount
0.067
0.096
−0.07
1
0

Polar surface area including P and S
0.36
−0.1
−0.2
0
1

Table 6: Observed and predicted biological activity of -CAIs by 2D QSAR model-2.

Molecule no.
Biological activity in
Predicted activity in for 2D QSAR model-2
Molecule no.
Biological activity in
Predicted activity in for 2D QSAR model-2

a1
−0.344717
−0.03583
P10
1.266859
1.259637

a2
−0.190249
−0.882354
P11
1.120772
1.091515

a4
−0.082413
−0.080626
P12
1.272709
1.060481

a5
0.464319
−0.106191
P13
1.272709
1.026872

a6
−0.30816
−0.044932
P14
0.788528
0.89279

a7
−0.263988
−0.504471
P15
2.308512
2.124939

a8
0.11921
−0.093422
u1
−0.190249
−0.03583

a9
0.13413
−0.128722
u2
0.632479
0.403403

a10
0.1422
0.38934
u3
0.67832
0.262013

a11
0.153019
0.143271
u4
−0.439697
−0.598791

a14
−0.19505
−0.786396
u5
1.136967
1.375718

a15
−0.040293
0.058489
u6
1.153646
1.207608

a16
−0.532544
0.079877
u7
1.162552
1.346787

a17
−0.068149
−0.136086
u8
1.174377
1.371611

a18
−0.35595
−0.038223
u9
0.95411
1.21467

a19
0.046485
−0.117271
u10
1.275984
1.232844

a20
0.085669
0.138466
u11
2.121827
1.420216

a23
0.174574
−0.04454
u12
0.525091
0.153663

a25
0.112519
−0.111599
u13
1.456193
1.536107

a26
−0.284564
0.416801
u14
−0.192447
−0.537819

a27
0.150512
0.064997
u15
−0.054696
0.449772

a41
−0.240392
−0.082426
u16
1.116353
1.301899

p1
0.750809
1.070581
u17
0.81894
1.295849

p2
1.106582
1.107905
u18
1.326855
1.338187

p3
1.258037
1.366532
u19
0.900615
1.271646

p4
1.258037
1.283997
u20
0.752133
0.486782

p5
1.104543
1.327902
u22
1.116085
0.527244

p6
1.255928
1.267606
u23
1.316884
1.396856

P7
1.255928
1.21467
u24
1.006908
1.274088

P8
1.115113
1.267606
u27
1.65065
1.181115

p9
1.266859
1.283997
u28
1.151463
1.143876

4. Conclusion

A set of 65 molecules of sulphonamide derivatives were subjected to 2D QSAR analysis using MLR to understand correlation between the physicochemical parameters and the β-CAI activity. A valid QSAR model for designing and predicting the β-CAI activity of newer sulphonamide derivatives has been successfully generated using MLR method. The 2D QSAR model (4) generated indicates that chi3cluster and k3alpha are positively contributing to β-CAI activity while SsssCHcount and Polar surface area including P and S, SssOcount are negatively contributing to β-CAI activity.

Acknowledgment

Authors would like to thank Principal of PDEA’s S. G. R. S. College of Pharmacy, Saswad, for providing facilities to complete this study.

References

C. T. Supuran, “Carbonic anhydrases: novel therapeutic applications for inhibitors and activators,” Nature Reviews Drug Discovery, vol. 7, no. 2, pp. 168–181, 2008.

A. Scozzafava, A. Mastrolorenzo, and C. T. Supuran, “Carbonic anhydrase inhibitors and activators and their use in therapy,” Expert Opinion on Therapeutic Patents, vol. 16, no. 12, pp. 1627–1664, 2006.

C. T. Supuran, A. Scozzafava, and A. Casini, “Carbonic anhydrase inhibitors,” Medicinal Research Reviews, vol. 23, no. 2, pp. 146–189, 2003.

Y. Xu, L. Feng, P. D. Jeffrey, Y. Shi, and F. M. M. Morel, “Structure and metal exchange in the cadmium carbonic anhydrase of marine diatoms,” Nature, vol. 452, no. 7183, pp. 56–61, 2008.

T. Stams and D. W. Christianson, “X-ray crystallographic studies of mammalian carbonic anhydrase isozymes,” in The Carbonic Anhydrases—New Horizons, W. R. Chegwidden, N. D. Carter, and Y. H. Edwards, Eds., pp. 159–174, Birkhäuser, Basel, Switzerland, 2000.

A. Thiry, J.-M. Dogné, B. Masereel, and C. T. Supuran, “Targeting tumor-associated carbonic anhydrase IX in cancer therapy,” Trends in Pharmacological Sciences, vol. 27, no. 11, pp. 566–573, 2006.

C. T. Supuran, A. Casini, A. Mastrolorenzo, and A. Scozzafava, “COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents,” Mini-Reviews in Medicinal Chemistry, vol. 4, no. 6, pp. 625–632, 2004.

C. T. Supuran, “Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity,” Expert Opinion on Therapeutic Patents, vol. 13, no. 10, pp. 1545–1550, 2003.

C. T. Supuran, A. Scozzafava, F. Mincione et al., “Carbonic anhydrase inhibitors. Part 60. The topical intraocular pressure-lowering properties of metal complexes of a heterocyclic sulfonamide: influence of the metal ion upon biological activity,” European Journal of Medicinal Chemistry, vol. 34, no. 7-8, pp. 585–595, 1999.

M. S. Kyllönen, S. Parkkila, H. Rajaniemi et al., “Localization of carbonic anhydrase XII to the basolateral membrane of H⁺-secreting cells of mouse and rat kidney,” Journal of Histochemistry and Cytochemistry, vol. 51, no. 9, pp. 1217–1224, 2003.

S. Elleuche and S. Pöggeler, “Evolution of carbonic anhydrases in fungi,” Current Genetics, vol. 55, no. 2, pp. 211–222, 2009.

M. Eriksson, J. Karlsson, Z. Ramazanov, P. Gardeström, and G. Samuelsson, “Discovery of an algal mitochondrial carbonic anhydrase: molecular cloning and characterization of a low-CO₂-induced polypeptide in Chlamydomonas reinhardtii,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 21, pp. 12031–12034, 1996.

A. K. C. So and G. S. Espie, “Cloning, characterization and expression of carbonic anhydrase from the Cyanobacterium synechocystis PCC6803,” Plant Molecular Biology, vol. 37, no. 2, pp. 205–215, 1998.

G. Amoroso, L. Morell-Avrahov, D. Müller, K. Klug, and D. Sültemeyer, “The gene NCE103 (YNL036w) from Saccharomyces cerevisiae encodes a functional carbonic anhydrase and its transcription is regulated by the concentration of inorganic carbon in the medium,” Molecular Microbiology, vol. 56, no. 2, pp. 549–558, 2005.

M. B. Guilloton, J. J. Korte, A. F. Lamblin, J. A. Fuchs, and P. M. Anderson, “Carbonic anhydrase in Escherichia coli—a product of the cyn operon,” Journal of Biological Chemistry, vol. 267, no. 6, pp. 3731–3734, 1992.

K. S. Smith, C. Jakubzick, T. S. Whittam, and J. G. Ferry, “Carbonic anhydrase is an ancient enzyme widespread in prokaryotes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 26, pp. 15184–15189, 1999.

R. S. Rowlett, “Structure and catalytic mechanism of the β-carbonic anhydrases,” Biochimica et Biophysica Acta, vol. 1804, no. 2, pp. 362–373, 2010.

M. R. Sawaya, G. C. Cannon, S. Heinhorst et al., “The structure of β-carbonic anhydrase from the carboxysomal shell reveals a distinct subclass with one active site for the price of two,” Journal of Biological Chemistry, vol. 281, no. 11, pp. 7546–7555, 2006.

T. Klengel, W.-J. Liang, J. Chaloupka et al., “Fungal adenylyl cyclase integrates CO₂ sensing with cAMP signaling and virulence,” Current Biology, vol. 15, no. 22, pp. 2021–2026, 2005.

C. Hansch, In Exploring QSAR: Fundamentals and Applications, in Chemistry and Biology, American Society, Washington, DC, USA, 1995.

F. Pacchiano, F. Carta, D. Vullo, A. Scozzafava, and C. T. Supuran, “Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides,” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 1, pp. 102–105, 2011.

Ö. Güzel, A. Maresca, R. A. Hall et al., “Carbonic anhydrase inhibitors. The β-carbonic anhydrases from the fungal pathogens Cryptococcus neoformans and Candida albicans are strongly inhibited by substituted-phenyl-1H-indole-5-sulfonamides,” Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 8, pp. 2508–2511, 2010.

I. Nishimori, T. Minakuchi, T. Kohsaki et al., “Carbonic anhydrase inhibitors: the β-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 13, pp. 3585–3594, 2007.

A. Bertucci, A. Innocenti, A. Scozzafava, S. Tambutté, D. Zoccola, and C. T. Supuran, “Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata,” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 2, pp. 710–714, 2011.

S. M. Monti, A. Maresca, F. Viparelli et al., “Dithiocarbamates are strong inhibitors of the beta-class fungal carbonic anhydrases from Cryptococcus neoformans, Candida albicans and Candida glabrata,” Bioorganic and Medicinal Chemistry Letters, vol. 22, no. 2, pp. 859–862, 2012.

M. Rami, A. Innocenti, J.-L. Montero, A. Scozzafava, J.-Y. Winum, and C. T. Supuran, “Synthesis of rhodamine B-benzenesulfonamide conjugates and their inhibitory activity against human α- and bacterial/fungal β-carbonic anhydrases,” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 18, pp. 5210–5213, 2011.

S. Isik, F. Kockar, M. Aydin et al., “Carbonic anhydrase inhibitors: inhibition of the β-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates,” Bioorganic and Medicinal Chemistry, vol. 17, no. 3, pp. 1158–1163, 2009.

I. Nishimori, T. Minakuchi, D. Vullo, A. Scozzafava, and C. T. Supuran, “Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates,” Bioorganic and Medicinal Chemistry, vol. 19, no. 16, pp. 5023–5030, 2011.

A. Innocenti, R. A. Hall, C. Schlicker et al., “Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal β-carbonic anhydrase from Candida albicans with sulfonamides,” Bioorganic and Medicinal Chemistry, vol. 17, no. 13, pp. 4503–4509, 2009.

Ö. Güzel, A. Maresca, A. Scozzafava, A. Salman, A. T. Balaban, and C. T. Supuran, “Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial β-carbonic anhydrases Rv1284 and Rv3273,” Journal of Medicinal Chemistry, vol. 52, no. 13, pp. 4063–4067, 2009.

A. Innocenti, R. A. Hall, C. Schlicker, F. A. Mühlschlegel, and C. T. Supuran, “Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with aliphatic and aromatic carboxylates,” Bioorganic and Medicinal Chemistry, vol. 17, no. 7, pp. 2654–2657, 2009.

B. Pothen, V. Singh, S. Kumar, and M. Tiwari, “Structural optimization of new class of selective carbonic anhydrase inhibitors: QSAR approach,” Indian Journal of Chemistry B, vol. 49, no. 2, pp. 224–233, 2010.

V-life MDS3.5 Vlife science technologies pvt. Ltd, 1 akshay residency, plot 50 anand park, aundh pune 411007

“Chemdraw ultra 8.0 and Chem3D ultra,” Tech. Rep., Cambridge Soft Corporation, Cambridge, Mass, USA, http://www.cambridgesoft.com.

R. G. Khalifah, “The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C,” Journal of Biological Chemistry, vol. 246, no. 8, pp. 2561–2573, 1971.

R. Veerasamy, H. Rajak, A. Jain, et al., “Validation of QSAR models-strategies and importance,” International Journal of Drug Design & Discovery, vol. 3, pp. 511–519, 2011.

A. Golbraikh and A. Tropsha, “Beware of q²,” Journal of Molecular Graphics and Modelling, vol. 20, no. 4, pp. 269–276, 2002.

A. Tropsha, P. Gramatica, and V. K. Gombar, “The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models,” QSAR and Combinatorial Science, vol. 22, no. 1, pp. 69–77, 2003.

H. Kubinyl, “Variable selection in QSAR studies. I. An evolutionary algorithm,” Quantitative Structure-Activity Relationships, vol. 13, no. 3, pp. 285–294, 1994.

R. P. Verma and C. Hansch, “An approach toward the problem of outliers in QSAR,” Bioorganic and Medicinal Chemistry, vol. 13, no. 15, pp. 4597–4621, 2005.